+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Translating an understanding of the pathogenesis of hepatic fibrosis to novel therapies

Translating an understanding of the pathogenesis of hepatic fibrosis to novel therapies

Clinical Gastroenterology and Hepatology 11(3): 224-31.E1-5

The response to injury is one of wound healing and fibrogenesis, which ultimately leads to fibrosis. The fibrogenic response to injury is a generalized one across virtually all organ systems. In the liver, the injury response, typically occuring over a prolonged period of time, leads to cirrhosis (although it should be pointed out that not all patients with liver injury develop cirrhosis). The fact that many different diseases result in cirrhosis suggests a common pathogenesis. The study of hepatic fibrogenesis over the past 2 decades has been remarkably active, leading to a considerable understanding of this process. It has been clearly demonstrated that the hepatic stellate cell is a central component in the fibrogenic process. It has also been recognized that other effector cells are important in the fibrogenic process, including resident fibroblasts, bone marrow derived cells, fibrocytes, and even perhaps cells derived from epithelial cells (i.e., through epithelial to mesenchymal transition or EMT). A key aspect of the biology of fibrogenesis is that the fibrogenic process is dynamic; thus, even advanced fibrosis (or cirrhosis) is reversible. Together, an understanding of the cellular basis for liver fibrogenesis, along with multiple aspects of the basic pathogenesis of fibrosis, have highlighted many exciting potential therapeutic opportunities. Thus, while the most effective anti-fibrotic therapy is treatment of the underlying disease, in situations in which this not possible, specific anti-fibrotic therapy is likely to not only become feasible, but will soon become a reality. The goal of this review is to highlight the mechanisms underlying fibrogenesis that may be translated into future anti-fibrotic therapies and to review the current state of clinical development.

(PDF same-day service: $19.90)

Accession: 036708067

Download citation: RISBibTeXText

PMID: 23305825

DOI: 10.1016/j.cgh.2013.01.005

Related references

Idiopathic interstitial pneumonias: translating our current understanding into novel therapies. Experimental Lung Research 31 Suppl 1: 41-46, 2006

Cystic Fibrosis: Translating Molecular Mechanisms into Effective Therapies. Annals of the American Thoracic Society, 2018

Translating Our Current Understanding of Ascites Management into New Therapies for Patients with Cirrhosis and Fluid Retention. Digestive Diseases 35(4): 402-410, 2017

Challenges in translating preclinical studies to effective drug therapies in idiopathic pulmonary fibrosis. American Journal of Respiratory and Critical Care Medicine 181(6): 532-533, 2010

Liver Fibrosis: From Pathogenesis to Novel Therapies. Digestive Diseases 34(4): 410-422, 2016

New therapies for hepatic fibrosis. Clinics and Research in Hepatology and Gastroenterology 39 Suppl 1: S75-S79, 2016

Recent understanding of IBD pathogenesis: implications for future therapies. Inflammatory Bowel Diseases 12(11): 1068-1083, 2006

Lung inflammation in cystic fibrosis: pathogenesis and novel therapies. Clinical Biochemistry 47(7-8): 539-546, 2014

Hepatic Fibrosis: Emerging Therapies. Digestive Diseases 33(4): 504-507, 2016

Current and prospective therapies for hepatic fibrosis. Comprehensive Therapy 21(6): 303-307, 1995

Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies. Expert Review of Respiratory Medicine 9(5): 633-654, 2016

CFTR-knockout neonatal ferrets model may be useful in the understanding of CF pathogenesis and developing therapies. Thorax 66(7): 584-584, 2011

Recent advances in pathogenesis and molecular targeted therapies of idiopathic pulmonary fibrosis.. Zhonghua Jie He He Hu Xi Za Zhi 32(12): 945-947, 2016

Therapies for hepatic fibrosis: real hope or just academic exercise?. Digestive and Liver Disease 36(11): 714-716, 2004

Nonalcoholic Steatohepatitis (NASH) and Hepatic Fibrosis: Emerging Therapies. Annual Review of Pharmacology and Toxicology, 2017